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Riassunto
Il cacnro della mammella è il tipo di cancro più frequente nelle donne.
Dati recenti suggeriscono che lo stile di vita e la dieta giocano un
ruolo fondamentale nello sviluppo e nella prevenzione del cancro
mammario (1). Le attuali conoscenze confermano che una dieta
salutare, come la dieta Mediterranea, caratterizzata da un’eleveta
assunzione di frutta, verdura, fibre, pesce e oli insaturi, in particolare
acidi grassi n-3, ha un effetto protettivo sul cancro al seno, mentre una
dieta tipicamente occidentale caratterizzata da un’alta assunzione di
grassi saturi, zuccheri raffinati, carne rossa e uno scarso apporto di
fibre aumenta il rischio di sviluppo di tale neoplasia.
I pomodori sono elementi chiave della Dieta Mediterranea. Sono
economici e facilmente conservabili, e in più sono un’eccellente fonte
di composti fitochimici con forti proprietà antiossidanti.Finora il
pomodoro non è mai stato valutato come alimento con potenziali
proprietà antitumorali perché ci si è focalizzati sui singoli composti
antiossidanti in esso contenuti come il licopene, β-carotene, ecc.
In questo studio abbiamo analizzato un possibile ruolo antineoplastico
dei pomodori. In particolare, abbiamo utilizzato gli estratti lipofili
totali di due cultivar del Sud Italia, il San Marzano e il Corbarino, che
meglio mimano l’assunzione di pomodoro attraverso la dieta, senza
isolare i singoli composti antiossidanti, o le vitamine, come spesso è
riportato in letteratura. Abbiamo scelto modelli in vitro di cancro
mammario, perché la maggior parte del licopene si accumula nella
mammella essendo un organo costituito principalmente da tessuto
adiposo.
Summary
Breast cancer is the most frequent type of cancer in women. Recent
data suggest that lifestyle factors including dietary factors play a
significant role in breast cancerdevelopment and survival(1).Current
knowledge suggests that a healthy/Mediterranean-like diet
characterized by high intake of fruit, vegetables, fiber, fish and
unsaturated oils, particularly n-3 fatty acids, has a protective effect on
breast cancer, whereas a typical Western diet characterized by high
intake of total/saturated fat, refined carbohydrates, processed and red
meat and low fiber intake is associated with poorer outcome.
Tomatoes are of specific interest because they are key elements of the
Mediterranean diet. Moreover, they are relatively cheap and easy to
store, and also because they are the main source of phytochemicals
with strong antioxidant properties. Whole tomato as a food with
potential anticancer properties has not been extensively evaluated so
far, because greater attention has been given to single antioxidant
compounds, such as lycopene, β-carotene, etc.
Here we presented our results on a possible antineoplastic role of
tomatoes without significantly affecting non-
tumorcells(primaryhuman skin fibroblasts). We used total lipophilc
tomato extracts of two Southern Italy cultivars, San Marzano and
Corbarino, which better mimics tomato intake by diet, without
isolating antioxidants, or vitamins, as often reported in the literature.
We chosein vitro models of breast cancer, because much of lycopene
accumulates in breast, an organ consists mainly of adipose tissue.
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1. Introduction
1.1 Breast cancer: epidemiology and etiology
Breast cancer is the most frequently diagnosed cancer in women
and one of the leading causes of cancer death for women.
Worldwide, over 1.3 million cases of invasive breast cancer are
diagnosed, and more than 450,000 women die from breast
cancer annually (2). According to GLOBOCAN 2012, breast
cancer is the second most common cancer in the world and so
far, the most frequent cancer among women with an estimated
1.67 million new cancer cases diagnosed in 2012 (25% of all
cancers). It is the most common cancer in women both in more
and less developed regions, with slightly more cases in less
developed (883,000 cases) than in more developed (794,000)
countries. Incidence rates vary nearly four-fold across the world
regions, with rates ranging from 27 per 100,000 in Middle
Africa and Eastern Asia to 92 in Northern America (Fig. 1).
Breast cancer ranks as the fifth cause of death from cancer
overall (522,000 deaths) and it is the most frequent cause of
cancer death in women in the Southern emisphere (324,000
deaths, 14.3% of total), it is the second cause of cancer death in
the Northern one (198,000 deaths, 15.4%) after lung cancer. The
range in mortality rates between world regions is less than that
for incidence because of the more favorable survival of breast
cancer in (high-incidence) developed regions, with rates ranging
from 6 per 100,000 in Eastern Asia to 20 per 100,000 in
Western Africa (Fig. 2).
The disease is caused by multiple genetic defects that can be due
to infectious and non-infectious factors, environmental and
lifestyle factors, e.g. diet, physical inactivity, obesity, alcohol
consumption, tobacco smoking (3). It is suggested that about
90% of cancers is linked to the environmental exposure (4, 5).
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The main strategy for a control of breast cancer would be
through primary prevention, followed by theidentification of
risk factors for cancer. There is a large amount of evidence that
the strongest factors that increase breast cancer risk in women
are: age above 65 years, genetic mutations in BRCA1 and/ or
BRCA2 genes (breast cancer susceptibility 1 and 2), high
mammographic breast density, atypical hyperplasia (relative
risk, PR>4); exposure to endogenous sex hormones, exposure to
high-dose of ionizing radiation (RR=2.1-4.0); age at menarche
<12 years, menopause above 55 years, no full-term pregnancies,
postmenopausal obesity, personal history of colon or other
gynecological cancers, long-term use of hormones containing
estrogen and progestin (RR=1.2-2.0) (6). The first basic factor
increasing breast cancer risk is patient’s age at the moment of
diagnosis of neoplastic disease. As it was mentioned above,
breast cancer is most frequently found in women around
menopause. It is significantly less frequent in women below 45
years of age, although recently, several cases of breast cancer in
under-forty women are documented (7). The analysis of
morbidity coefficients for the Polish population has indicated a
linear increase in the group of women aged between 40 and 59
years, then it reaches a plateau with a slight decreasing tendency
in women aged 70 and older. A very interesting correlation can
be observed between the age when neoplastic disease is
diagnosed and the expression of the estrogen receptor found in
the examined tumor tissue. Neoplasms showing estrogen
receptor overexpression ER (+) are characterized by a frequency
increasing with age as opposed to ER (–) tumors, which occur
more frequently up to 50 years of age and then reach a plateau.
This phenomenon explains an increased percentage of ER (+)
tumors diagnosed in women after menopause (8).
Another intrinsic factor conditioning the occurrence of breast
cancer is familial susceptibility to this type of neoplasm.
Intensive studies have been conducted in the recent decades,
which led to  identification of genes whose function disorder is
associated with an increased risk of occurrence of malignant
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breast or ovarian cancer. The most important are genes BRCA1
and BRCA2 fulfilling the function of tumor suppressor genes in
a cell. The occurrence of changes in the coding sequence may
lead to the development of hereditary syndromes called HBC-SS
(Hereditary Breast Cancer Site Specific) or HBOC (Hereditary
Breast Ovarian Cancer) syndrome, which manifest themselves
in the form of breast and/or ovarian cancer. The correlation of
epidemiologic and population studies has allowed for the
estimation of the number of familial breast and/or ovarian
cancer cases. They constitute about 10% of all newly diagnosed
neoplasms of these organs (9). Identification of mutations in
BRCA1 or BRCA2 genes is associated with an increased risk of
occurrence of breast and/or ovarian cancer in 65% or 45% of
mutation carriers, respectively, depending on the mutation type
(9).
A high endogenous estrogen level is a well-defined risk factor
contributing to a higher incidence of breast cancer. The analysis
of prospective studies confirmed a strong association between
increasing concentrations of sex hormones (total estradiol, free
estradiol, estrone, estrone sulfate, androstenedione,
dehydroepiandrosterone, dehydroepiandrosterone sulfate and
testosterone) in postmenopausal women and a higher breast
cancer risk (10).
The relationship between oral contraception and the risk of
breast cancer still remains controversial.Some studies have
suggested that using oral hormonalcontraceptives increases the
risk of breast cancer by24% compared to women who have
never used them (8), and the largest incidence increase is
observed in thecourse of using the contraception. On the other
hand,the reanalysis of epidemiological studies showed a littleor
even no association between the risk of breast cancer and oral
contraception (11).
Another factor increasing the risk of developing breast cancer is
exposure to ionizing radiation, especially at a young age
(numerous X-rays, radiation therapy in the treatment of
dermatological lesions, radiation therapy in the treatment of
Introduction
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cancer) (12).
A clear risk factor for endometrial cancer and breast cancer in
postmenopausal women is overweight. Epidemiological studies
suggest that there are links between fat intake and breast cancer.
It was hypothesized that the high-fat or high-calorie diets,
leading to an increase in the fat content in the body, can affect
the development of breast cancer. This is done by raising the
circulation levels of certain hormones, prolactin and estrogen,
which may facilitate the development of breast cancer. It is
believed that food fat, or fat contained in the body adversely
affects the immune system, which becomes less efficient in
combating emerging cancer cells (13).
Studies show a link between obesity and risk of breast cancer in
postmenopausal women. Most cases of breast cancer in
postmenopausal women are sensitive to estrogen, and estrogen
produced in  adipose tissue is conducive to the formation of a
tumor (14). Obesity causes secretion of inflammatory factors
that stimulate aromatase enzyme responsible for the steroid
hormone biosynthesis (15). This affects the conversion of
androgens into estrogen in adipose tissue. Neuhouseret al. (16)
also confirm that obesity is closely linked to the growth of
invasive breast cancer in postmenopausal women compared to
women of normal weight.
1.2 Classification of breast cancer
Breast cancer is a heterogeneous disease, including several
clinicopathological subtypes with different biological behavior,
clinical risk factor, natural histories, response to individualized
therapy and prognosis (17). In the past, management of breast
cancer was essentially based on histopathological grade and
TNM stage, which had achieved some consensus (17).
Breast cancer is classified into five subtypes using the
expression of four markers: estrogen receptor (ER), proges-
terone receptor (PR), human epidermal growth factor receptor 2
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(HER2 and Ki-67). These markers allow classification of breast
cancer tumors as: luminal A (ER-and/or PR-positive/HER2-
negative/low Ki-67), luminal B (ER- and/or PR-positive/HER2-
negative/high Ki-67), HER2-positive luminal B (ER- and/or PR-
positive/HER2 overexpression/any Ki-67), non-luminal HER2-
positive (ER and PR absent/HER2 overexpression), and triple
negative breast cancer -TNBC- (ER and PR absent/HER2-
negative) (17). Here, we will show results obtained in two breast
cancer cell lines representing in vitro models of triple positive
breast cancer (MCF-7) and TNBC (MDA-MA-231). Generally,
hormone receptor expressing breast cancers have a more
favorable prognosis than either those with HER2 amplification
or those that are triple negative (18). While all breast tumor
types may be treated with chemotherapy, therapeutic options in
both early and late stage breast cancer are affected significantly
by the expression of these three markers. Tumors that express
ER and PR are treated with agents that interfere with hormone
production or action. Tumors that have amplified HER2 are
treated with agents that inhibit HER2. These targeted therapies
are the mainstay of the successful outcomes seen in hormone
receptor positive and HER2 amplified tumors. Both early stage
and advanced TNBC tumors are treated with predominantly
chemotherapy (19). The discovery of several clinicopathological
subtypes of breast carcinoma has led to a better understanding of
molecular biology and has produced an effect on the risk
assessment of recurrence and clinical treatment of breast cancer.
1.3 Diet and breast cancer
Due to international variance in cancer rates, geography-related
dietary habits, importance of diet in the development of cancers
including BC, the association between dietary pattern and BC risk
has been suggested and hundreds of studies have examined this
association during last 35 years. According to previous research,
dietary factors were thought to be responsible for about 30% of all
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cancers in developed countries and for 20% in developing
countries (20, 21). It is commonly accepted that a diet of the
Western developed countries is high in animal products, fat and
sugar. In contrast, a diet of developing countries is more “healthy”
basing on starchy staple foods with low consumption of animal
products, fat and sugar (22). The diet may impact all stages of
breast cancer carcinogenesis. For example, chemical carcinogens,
such as heterocyclic amines, polycyclic aromatic hydrocarbons,
and nitrites that may be produced in a high temperature processed
meat can damage DNA and initiate carcinogenesis. In addition, the
compounds present in an unhealthy diet may stimulate formation
of IGF-1, increase concentrations of circulating endogenous sex
hormones, thus influence the initiation, promotion and progression
of tumor stages. In turn, red meat is rich in heme iron which is
necessary for production of hydroxyl radical via the Fenton
reaction-the most biologically toxic oxygen species involved in
oxidative stress. Thus, iron ions may indirectly influence on
cytoplasmic and nuclear signal transduction pathways (23, 24). In
contrast, the healthy diet (rich in antioxidants) may influence on
DNA repair, metabolic detoxification and decrease of estrogens
(25).
1.4 Mediterranean diet
Mediterranean diet, which is a traditional dietary pattern of the
inhabitants of the Mediterranean countries, is considered to be
one of the healthiest diet rich in many nutrients. This is not only
due to its taste, but also a varied menu based on a large amount
of fresh vegetables and fruits, fish, legumes, whole grains, olive
oil and herbs. However, the main cause of the promotion of the
Mediterranean diet is its health-related properties.
Fundamentals of the Mediterranean diet have been formulated
on the basis of eating habits of people living in the
Mediterranean countries. The following common features have
been found in their diet:
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 high consumption of fruits, vegetables, legumes, nuts, whole
grains,
 high consumption of olive oil as the main source of fat,
 high consumption of spices such as oregano, garlic, basil,
thyme, rosemary, sage,
 moderate consumption of fish and seafood,
 moderate consumption of milk and dairy products (mainly
cheese and yoghurt),
 moderate consumption of wine, mainly for meals,
 low consumption of meat and meat products,
 consumption of local, seasonal fresh produce.
Health properties of a traditional Mediterranean diet result from
consumption of large quantities of vegetable products that are a
source of bioactive components. These components have anti-
cancer properties that is, carotenoids, antioxidant vitamins
(vitamin C, E, A), lycopene, resveratrol, flavonoids,
polyphenols and dietary fiber. Mediterranean diet is
characterized by a favorable ratio of polyunsaturated fatty acids
of omega-6 family to omega-3, which is about 2 : 1. In other
European countries and the United States, this ratio is 10 : 1 and
20 : 1, respectively.
The traditional Mediterranean diet was popularized since 1995
using the world famous pyramid representation that graphically
highlights the food groups to be consumed daily, weekly, or less
frequently (26), yet, a new Mediterranean diet pyramid was
recently proposed. The new pyramid, effectively, reflects the
changing process that the Mediterranean diet is
undergoingwithin the Mediterranean societies (Fig. 3). The
recommendations target the healthy adult population (18-65
years old) and it should be adapted to the special needs of
children, pregnant women and those suffering from health
conditions.
Over the past three decades numerous studies have documented
that products of Mediterranean diet play a critical role against
cancer (27, 28, 29). For example, Alegre et al. (29) reported that
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olive oil has potential not only to decrease breast cancer risk but
also aggressiveness of this disease. In addition, Berrino (30)
conducted a PREDIMED study to evaluate the effect of 2
interventions with Mediterranean diet (Mediterranean diet
supplemented with extra-virgin olive oil, a Mediterranean diet
supplemented with mixed nuts) vs the advice to follow a low-fat
diet (control) on breast cancer incidence.After a median follow-
up of 4.8 years, the author identified 35 confirmed incident
cases of breast cancer. Observed rates (per 1000 person-years)
were 1.1 for the Mediterranean diet with extra-virgin olive oil
group, 1.8 for the Mediterranean diet with nuts group, and 2.9
for the control group. These results suggest a beneficial effect of
a Mediterranean diet supplemented with extra-virgin olive oil in
the primary prevention of breast cancer.
Figure 3
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1.5 Tomato and breast cancer
Tomatoes may be included among the most representative
elements of the Mediterranean diet. They are relatively cheap
and easy to store and they are the main source of micronutrients
such as potassium, folate and the vitamins A, C and E, if
compared with other widespread vegetables. In addition to their
micronutrient benefits, tomatoes also contain important
phytochemicals, like polyphenols and carotenoids, especially
lycopene, with strong antioxidant properties (31) (Table 1). The
latter are not essential nutrients and are not required by the
human body for sustaining life, but they have protective, or
disease preventive properties.
Various epidemiologic studies have correlated risk of cancer at
various body sites, with intake of tomatoes and tomato-based
products. Evidence for beneficial effects was the strongest for
cancers of the prostate, lung and digestive tract. A consistent
pattern of protection by high intake of tomatoeswas also seen in
cervix, pancreas, colorectum, esophagus, oral cavity, pharynx
and breast cancer (32, 33). In particular, tomato plays a
fundamental chemopreventive role among postmenopausal
women at high risk for developing breast cancer, through the
insulin-like growth factor-I (IGF-I) and IGF-binding protein-3
(IGFBP-3) signaling pathway (34). IGF-I is a mitogenic and
antiapoptotic peptide hormone that is involved in cell regulation
and tumorigenesis. The effects of IGF-I are regulated by binding
to IGFBP-3. Animal and human studies show that increased
levels of both IGF-I and IGFBP-3 are associated with breast
cancer risk (35-37). Possible benefits from tomatoes are thought
to be derived from lycopene: human studies indicate that
lycopene interacts with IGF-I and IGFBP-3 and can eliminate
free oxygen radicals-thereby preventing DNA mutation, cell-
cycle alteration, and apoptotic disruption (34).In 2006, Nahum
et al. (38) showed that lycopene and all-trans retinoic acid
(atRA) inhibit IGF-I induced proliferation of MCF-7 breast
cancer cells through reduction in cyclin D1 levels. Dietary
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lycopene and others carotenoids have also been shown to inhibit
estrogen signaling of 17β-estradiol that may attenuate the effects
of hormone-dependent malignancies (39). In vitro, carotenoids
(lycopene, phytoene, phytofluene, and beta-carotene) inhibit
breast cancer cell (T47D and MCF-7) proliferation induced by
either 17β-estradiol, or genistein by slow-down of cell-cycle
progression from G1 to S phase. Moreover, carotenoids inhibit
estrogen-induced transactivation of ERE mediated by both
estrogen receptors (ERs) ERalpha and ERbeta.
Considering incidence and relevance of breast cancer, relatively
few studies examined its relationship to tomato, or lycopene
intake. FDA identified four case-control studies (40-43) that
examined the association between tomato intake and risk of
breast cancer. Two of these studies (40, 41) were not considered
for further review because they had scientific deficiencies. On
the basis of the others two studies, FDA concluded that there
was no credible evidence supporting an association between
tomato or tomato-based food consumption and breast cancer risk
(42, 43).
Introduction
12
Table 1
Introduction
13
1.6 Scientific hypothesis and aim of the work
Whole tomato as a food with potential anticancer properties has
not been extensively evaluated so far, because greater attention
has been given to single antioxidant compounds, such as
lycopene, β-carotene, etc.These bioactive natural compounds
have been long used for healing purposes. Although variousin
vitro and in vivo studies focused on the possible anti-
carcinogenic properties of food-derived principles, in order to
identify novel drugs for cancer chemoprevention and/or therapy,
they usually investigate the effects of pure phytochemicals. Far
fewer studies, in fact, focus upon interventions with whole
foods, or processed food products. Here, we aimed to evaluate
the biological and molecular effects of treatment with total
lipophilic extracts from the two Italian tomato cultivars, San
Marzano and Corbarino, using as biological system two in vitro
model of breast cancer.
Materials and Methods
2. Materials and Methods
2.1 Cell culture
Two breast cancer (MCF-7 and MDA-MB-231) and a primary
human skin fibroblasts (HSF) cell lines were used. MCF-7 cell
line was isolated in 1970 from a 69 year sold Caucasian woman.
MCF-7 cells are useful for in vitro breast cancer studies because
the cell line has retained several ideal characteristics particular
to the mammary epithelium. These include the ability for MCF-
7 cells to process estrogen, in the form of estradiol, via estrogen
receptors in the cell cytoplasm. This makes the MCF-7 cell line
an estrogen receptor (ER) positive control cell line (44). MDA-
MB-231 was established in 1970 from primary tumor of a 51
years old Caucasian woman. MDA-MB-231 is a triple negative
breast cancer cell line because it do not express ER,  progesteron
receptor (PR), and do not have HER-2/Neu amplification (45).
Primary human skin fibroblasts were kindly provided by
Michele Fimiani, Giancarlo Mariotti, and Stefania Mei
(University of Siena, Italy) (46). MCF-7 and HSF cell lines were
cultured and maintained in DMEM while MDA-MB-231 cell
line in RPMI supplemented with 10% fetal bovine serum,
100U/mL of penicillin and 0.1mg/mL of streptomycin. All the
cell lines were incubated at 37°C in a 5% CO2 incubator.
2.2 Cell growth curve analysis
1.0×105 cells were plated in tissue culture dishes (60 mm)
containing culture medium with 10% FBS. MCF-7 and MDA-
MB-231 cell lines were treated with 15, 30 and 60 µg/mL of
total lipophilic extracts of San Marzano (SM) and Corbarino
(COR) cultivars and 1.5, 3 and 6 µL/mL of DimethylSulfoxide
(DMSO) as control. After 24, 48 and 72 hours (h) culture
medium was removed, adherent cells were trypsinized and the
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total number of adherent cells in each well was quantified using
a Burker chamber. The cell counts for 3 wells/time-point were
averaged for each group and data were used to draw growth
curves. HSF cell line was treated with 30 µg/mL of total
lipophilic extracts of tomato and counted after 24, 48 and 72 h
following the same procedure.
2.3 Soft Agar colony formation assay
Soft agar colony formation assay was performed to evaluated
anchorage-independent cell growth. Briefly, a base layer of agar
(0.5%) in cell culture media was plated in twenty-four-well
plates. MCF-7 and MDA-MB-231cells were mixed in top layer
agar solution (0.3%) plus 30 µg/mL of total lipophilic extracts
of SM and COR cultivars and 3 µL/mL of DMSO, as control,
and then plated at a density of 3000 and 8000 cells per well,
respectively. Each treatment group was plated in triplicates.
Plates were incubated at 37°C in a 5% CO2-containing
humidified incubator. After 14 days of colony growth, cells
were stained with 0.5 mg/mL nitrobluetetrazolium, and colonies
were visualized and counted with Image Pro-Plus Software
(Media Cybernetics).
2.4 Scratch test
Cells were plated in tissue culture dishes (60 mm) and grown to
~100% confluency before scratching with a sterile P10 pipette
tip, across the monolayer. Cell debris were removed by washing
in PBS 1x and cells were cultured in DMEM and 10% FBS
supplemented with 30 µg/mL of tomato extracts and 3 µL/mL of
DMSO, as control. Area of the scratch was measured at 0, 24,
48 and 72 h and quantification was performed by measuring the
area of cell migration at different time points compared to the
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scratch area at 0 h. Each experiment was repeated 3 times.
2.5 Cell Cycle analysis
Cells, after 72h of incubation with 30 µg/mL of tomatoes
extracts and 3 µl/ml of DMSO, were trypsinized and 1x106 cells
were fixed with 70% ethanol at −20°C overnight. Cells were
washed and stained with 5 μg/mL propidium iodide and 20
μg/mL RNAase at 4°C overnight. DNA content and cell cycle
distribution were analyzed by FACS.
2.6 Western Blotting
Cell extracts containing 50γ protein were separated on sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to nitrocellulose membranes. The
membranes were then blocked in Tris-buffered saline (TBS)
with 0.1% Tween 20 containing 5% nonfat dry milk for 1 hour
at room temperature. Subsequently, the membranes were
incubated with specific primary antibodies at 4°C overnight:
mouse anti-pRb/p105 (1:250), mouse anti-pRb2/p130 (1:250),
rabbit anti-p107 (1:100) and -p27Kip1 (1:250), and rabbit anti-
GAPDH (1:1000). After washing, the membranes were
incubated with secondary antibodies at the appropriate dilutions
for 1 hour at room temperature and detected using enhanced
chemiluminescence ECL substrate Kit. Protein expression levels
were normalized to GAPDH.
2.7 Statistical analysis
Statistical analyses were performed using the GraphPad
Software, version 5.01 for Windows. Statistically significant
differences between the means of multiple matched groups were
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evaluated by one-way repeated measures Anova, with either
Dunnett post-test, to compare all data versus control (growth
curve analysis). P<0.05 was considered to indicate a statistically
significant difference.
2.8 San Marzano and Corbarino tomato extracts, composition and
antioxidant activity
Tomato extracts were provided under lyophilized form by the
research group coordinated by Dr. Barbara Nicolaus from
Council of National Research, Institute of Biomolecular
Chemistry, Pozzuoli, Italy. The aforementioned group also
performed the analysis of the antioxidant activity and lycopene
composition of our extracts, as previously described (47).
Results
3. Results
3.1 Dose response analysis of tomato lipophilic extracts
Primarily, we analyzed possible biological effects of tomatoes
lipophilic  extracts on cell growth. We treated cells with 15, 30
and 60 μg/mL of tomato extracts and analyzed proliferation at
24, 48 and 72 h. Results in Fig.4 showed that 30 µg/mL of SM
represent the most effective concentration in inhibiting MCF-7
cell growth, although COR extract also exerted a good
inhibitory effect. MDA-MB-231 were impaired in their growth
by 30 µg/mL of COR and by a lesser extend by SM. In both cell
lines, the highest cell growth inhibitory effect was
corresponding to 30 µg/mL of extract. Overall, we did not
observe a dose-response anti-proliferative effect of the whole
tomato extracts (Fig. 5, 6) and focused for further experiments
on the 30 µg/mL which showed a good anti-proliferative
efficacy in both cell lines. The anti-proliferative effect of tomato
extracts was particularly consistent after 72 hours of incubation.
No toxic effects were observed on HSF cell line after treatment
with 30 µg/mL of both lipophilic extracts (Fig. 7).
3.2 Inhibition of cell growth in semisolid cell culture medium
We investigated the effect of tomato extracts on anchorage-
independent growth of cancer cells in a typical soft-agar assay.
After a 14 days incubation in soft agar, control colonies of
MCF-7 and MDA-MB-231 cells were found more numerous
and larger than COR treated cells, whereas no differences were
observed between control cells and SM extract treated cells (Fig.
8).
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3.3 Inhibition of cell migration
We performed a scratch test assay to investigate possible
tomatoes effects on cancer cell migration, in order to analyze
another biological effect typical of neoplastic growth. All
tomato extracts significantly inhibited migration in both cell
lines. After 24 hours of incubation, MDA-MB-231 control cells
showed a faster rate of injury repair compared with treated cells,
whereas, MCF-7 cell line exhibited the same effect after 72
hours (Fig. 9).
Figure 9 b
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3.4 Tomato extracts influenced cell cycle
To investigate whether the inhibitory effects of tomato extracts
were due to an arrest of cell cycle, we performed the analysis
of cell cycle by staining with PI and reading by FACS. In both
cell lines, we saw a slowdown of cell cycle, in particular a gain
in G0/G1 phase and a significant decrease in S phase (Fig. 10).
3.5 Tomato extracts regulate pocket proteins expression
We hypothesized that the inhibition of cancer cell growth and
migration induced by tomato extracts could be mediated by
pocket proteins, key regulators of cell cycle. Hence, expression
levels of the pRb/p105, pRb2/p130 and p107, were detected by
Western Blotting in order to investigate possible molecular
pathways involved in the previously observed biological
phenomena. In both cell lines, tomato extracts induced a strong
increase of pRb2/p130 expression levels, especially upon
treatment with COR, that compensate the reduction of
pRb/p105 expression levels (only in MCF-7). In MCF-7 cell
line, we also observed a higher expression level of p107 in
treated cells than in control, whereas in MDA-MB-231 no
particular differences were observed between control and
treated cells. Finally, MCF-7 showed upregulation of p27Kip1,
a cell cycle inhibitor, as consequence of COR treatment (Fig.
11). In conclusion, these observation at the molecular level
seem to explain the biological effects observed following
treatment with tomato extracts, and supported the hypothesis
that tomatoes may hinder neoplastic features, by influencing
cell cycle, one of the most important events of cells number
control.
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3.6 Tomato antioxidant activity and their lycopene content
Antioxidant activity of lipophilic extracts evaluated by ABTS
method is reported in the Figure 12. We observed that the SM
variety showed a greater antioxidant power, if compared to
COR.Lipophilic extract from each sample was analyzed by
reversed-phase High-Performance-Liquid-Chromatography
(HPLC), in order to evaluate lycopene contents. Data shown in
Table 1, displayed that SM content of lycopene is almost
double, if compared to COR (7,50 mg /100 g of fresh product
versus 4,20 mg/100 g of fresh sample). These data were kindly
provided by a research group of the Council of National
Research, Institute of Biomolecular Chemistry, Pozzuoli, Italy,
with whom we collaborate.
Figure 11
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SAMPLE
VOLUME OF
HOMOGENATE
(mL)
VOLUME OF
IDROPHILIC
PHASE
(mL)
LYCOPENE
CONTENT
IN 100 g OF
FRESH
SAMPLE
(mg)
COR 100 mL 53 mL 4,20 mg
SM 92 mL 56 mL 7,50 mg
Figure 12
Table 2
Discussion
4. Discussion/Conclusions
In the last years, growing interest about food plants and their
derivatives arose in scientific community because of a powerful
role in neoplasms prevention. Fresh and carved tomatoes are
typical of Italian diet, which represents a sort of subtype of
Mediterranean diet, whose healthiness is worldwide approved.
Their consumption is also diffuse because of their cheapness
and easiness of storage. Beneficial effects of tomato
consumption on human health are generally attributed to
carotenoids, particularly to lycopene, although they are also an
excellent source of vitamins (A, C, and E) and flavonoids.
Epidemiological studies showed a consistent inverse
relationship between tomato consumption and the risk of various
neoplasms. So far, most studies analyzed the effects of
individual compounds, especially lycopene, whereas our study
is focused on assessing, in vitro, the effects of lipophilic tomato
extracts on breast cancer cell lines, hence considering the food
not only its bioactive compounds. We firstly investigated
possible biological effects, such as cell growth and migration
impairment. Actually, we found that both tomato cultivars were
effective in inhibiting both cell growth, and migration, also in
semisolid cell culture medium in MCF-7 and MDA-MB-231
cell lines. The effects induced by COR treatment  were
relatively surprising because of its lower amount of lycopene
and, consequently, a lower antioxidant capability. However, this
might be in accordance to previous observations suggesting that
antioxidants anticancer effects are less effective in reducing
more aggressive neoplastic behavior.Watson, reported various
papers showing that in advanced stage neoplasms, antioxidants
compounds become pro-tumor development, because they
contribute to protect cancer cells by damages induced by ROS
(48). Hence, compounds that may help in preventing cell
transformation, in the fourth stage tumors are metabolized more
efficaciously by cancer cells, which can take advantages of their
Discussion
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properties. Watson highlighted, then, the failing of strategies
also based on vitamin supplements in advanced stage tumors.So,
although our experiments were focused on testing the effects of
whole vegetables, our results  were in accordance with the
hypothesis that when a cancer is progressed, considering
antioxidant compounds, the less is more. In our study we
highlighted how tomato extracts affect different molecular
pathways. Upregulation of pocket protein togheter with the
increase of the cell cycle inhibitor p27Kip1, controlled cell cycle
causing cell block in G0/G1 phase. Hence, observed biological
effects are supported by molecular mechanisms among which
we considered only cell cycle regulation, so further
investigations will be necessary to better analyze other pathways
involved.
In conclusion our data pave the way for future investigations
aimed at assessing whether diet implementation with continuous
consumption of tomatoes and its processed forms might be
effective for cancer prevention and supporting therapy,
considering that dietary intake of tomatoes is generally judged
safe (49). In particular, our data show that tomatoes in totoact as
potent anticarcinogenic agents, which may help to support
breast cancer therapy strategies.
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